vincristine indications/contra

Stem definitionDrug idCAS RN
vinca alkaloids 2825 57-22-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vincristine
  • (+)-Vincristine
  • leucristine
  • vincristin
  • vinkristin
  • 22-oxo-vincaleukoblastine
  • vincristine sulfate
  • oncovin
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
  • Molecular weight: 824.97
  • Formula: C46H56N4O10
  • CLOGP: 4.04
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 3
  • TPSA: 171.17
  • ALOGS: -4.44
  • ROTB: 10

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
July 10, 1963 FDA

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 9610.06 51.08 2440 19873 16535 3347011
Neutropenia 5008.89 51.08 1675 20638 31711 3331835
Sepsis 2501.89 51.08 1000 21313 31373 3332173
Thrombocytopenia 2408.74 51.08 997 21316 34271 3329275
Infection 2322.61 51.08 887 21426 24515 3339031
Off label use 1984.17 51.08 991 21322 52986 3310560
Pyrexia 1859.50 51.08 1088 21225 80027 3283519
Disease progression 1795.81 51.08 790 21523 31469 3332077
Myelodysplastic syndrome 1789.15 51.08 506 21807 5141 3358405
Bone marrow failure 1718.87 51.08 538 21775 7949 3355597
Mucosal inflammation 1700.42 51.08 526 21787 7457 3356089
Haematotoxicity 1657.06 51.08 392 21921 1782 3361764
Pancytopenia 1553.01 51.08 611 21702 18209 3345337
Hepatitis B 1551.96 51.08 380 21933 2053 3361493
Acute myeloid leukaemia 1523.51 51.08 438 21875 4735 3358811
Anaemia 1492.89 51.08 822 21491 53511 3310035
Leukopenia 1383.63 51.08 536 21777 15287 3348259
Neuropathy peripheral 1362.76 51.08 539 21774 16268 3347278
Posterior reversible encephalopathy syndrome 1285.51 51.08 347 21966 2907 3360639
Pneumonia 1277.87 51.08 814 21499 69329 3294217
Death 1200.39 51.08 1068 21245 151256 3212290
Septic shock 1158.66 51.08 439 21874 11745 3351801
Tumour lysis syndrome 1090.69 51.08 284 22029 2035 3361511
Venoocclusive liver disease 1049.96 51.08 248 22065 1114 3362432
Neutropenic sepsis 894.67 51.08 251 22062 2455 3361091
Product use issue 875.03 51.08 388 21925 15613 3347933
Pneumocystis jirovecii pneumonia 857.85 51.08 262 22051 3528 3360018
White blood cell count decreased 838.97 51.08 433 21880 24514 3339032
Disease recurrence 834.25 51.08 277 22036 4957 3358589
Febrile bone marrow aplasia 791.59 51.08 189 22124 896 3362650

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01CA02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Vinca alkaloids and analogues
MeSH PA D050256 Antimitotic Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000972 Antineoplastic Agents, Phytogenic
MeSH PA D050258 Mitosis Modulators
MeSH PA D050257 Tubulin Modulators
FDA EPC N0000175612 Vinca Alkaloid
FDA Chemical/Ingredient N0000007780 Vinca Alkaloids

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Acute lymphoid leukemia indication 91857003 DOID:9952
Diffuse non-Hodgkin's lymphoma, large cell indication 109969005
Hodgkin's disease indication 118599009 DOID:8651
Non-Hodgkin's lymphoma indication 118601006 DOID:8675
Burkitt's lymphoma indication 118617000 DOID:8584
Rhabdomyosarcoma indication 302847003 DOID:3247
Nephroblastoma indication 302849000 DOID:2154
Follicular non-Hodgkin's lymphoma indication 308121000
Neuroblastoma indication 432328008 DOID:769
Mycosis contraindication 3218000 DOID:1564
Hyperbilirubinemia contraindication 14783006 DOID:2741
Obstruction of bile duct contraindication 30144000 DOID:13580
Viral disease contraindication 34014006 DOID:934
Hyperuricemia contraindication 35885006 DOID:1920
Charcot-Marie-Tooth disease contraindication 50548001 DOID:10595
Hepatic failure contraindication 59927004
Leukopenia contraindication 84828003 DOID:615
Bacterial infectious disease contraindication 87628006 DOID:104
Peripheral motor neuropathy contraindication 95663000 DOID:683
Neuromyopathy contraindication 255522009 DOID:440
Uric acid renal calculus contraindication 274401005
Pregnancy, function contraindication 289908002
Peripheral nerve disease contraindication 302226006 DOID:574
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Polyneuropathies contraindication
Protozoal Infection contraindication
Astrocytoma, anaplastic off-label use 55353007 DOID:3078
Ewing's sarcoma off-label use 76909002 DOID:3369
Chronic lymphoid leukemia, disease off-label use 92814006 DOID:1040
Multiple myeloma off-label use 109989006 DOID:9538
Mycosis fungoides off-label use 118618005 DOID:8691
Small cell carcinoma of lung off-label use 254632001 DOID:5409
Glioblastoma multiforme of brain off-label use 276828006 DOID:3073
Primary cutaneous T-cell lymphoma off-label use 400122007
Ovarian Germ Cell Tumor Carcinoma off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.02 acidic
pKa2 13.81 acidic
pKa3 7.2 Basic
pKa4 6.58 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5MG/5ML (1MG/ML) MARQIBO KIT TALON THERAP N202497 Aug. 9, 2012 RX INJECTABLE, LIPOSOMAL INTRAVENOUS 6723338 March 31, 2020 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
5MG/5ML (1MG/ML) MARQIBO KIT TALON THERAP N202497 Aug. 9, 2012 RX INJECTABLE, LIPOSOMAL INTRAVENOUS 7887836 March 31, 2020 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5MG/5ML (1MG/ML) MARQIBO KIT TALON THERAP N202497 Aug. 9, 2012 RX INJECTABLE, LIPOSOMAL INTRAVENOUS Aug. 9, 2019 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tubulin beta Structural INHIBITOR SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Multidrug resistance-associated protein 7 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance protein 1 Transporter WOMBAT-PK
Tubulin Structural IC50 5.74 CHEMBL

External reference:

scroll-->
IDSource
DB00541 DRUGBANK_ID
4019971 VUID
N0000148056 NUI
C0042679 UMLSCUI
6785 IUPHAR_LIGAND_ID
D02197 KEGG_DRUG
5J49Q6B70F UNII
1440 INN_ID
11202 RXNORM
23079006 SNOMEDCT_US
387126006 SNOMEDCT_US
d00401 MMSL
387427007 SNOMEDCT_US
75292001 SNOMEDCT_US
4019971 VANDF
7308 MMSL
N0000007223 NDFRT
N0000148056 NDFRT
004894 NDDF
CHEMBL90555 ChEMBL_ID
CHEMBL501867 ChEMBL_ID
5978 PUBCHEM_CID
2068-78-2 SECONDARY_CAS_RN
D014750 MESH_DESCRIPTOR_UI
CHEBI:28445 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Vincasar PFS HUMAN PRESCRIPTION DRUG LABEL 1 0703-4402 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 14 sections
Vincasar PFS HUMAN PRESCRIPTION DRUG LABEL 1 0703-4412 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 14 sections
Marqibo HUMAN PRESCRIPTION DRUG LABEL 1 20536-322 KIT 5 mg None NDA 20 sections
VinCRIStine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 61703-309 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 14 sections